The FDA has approved GlaxoSmithKline’s Zejula as first-line maintenance treatment for women with platinum-responsive ovarian cancer, competing against AstraZeneca and Merck & Co’s class rival ...

A second cohort in the trial (Part 2) is looking at the combination of Jemperli and GSK’s PARP inhibitor Zejula (niraparib) as maintenance in MMRp/MSS tumours, comparing it to placebo.

Involves transaction of at least 0.5% of the listed shares of a company. What was Glaxosmithkline Pharmaceuticals Ltd share price previously? Glaxosmithkline Pharmaceuticals Ltd share price was up ...

After hours: March 7 at 7:55:40 p.m. EST Loading Chart for GSK ...

The Indian Sugar Mills Association (ISMA) has lowered its sugar production estimate for 2024-25 to 264 lakh tons, citing lower sugarcane yields and ethanol production. The revised estimate includes ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

GlaxoSmithKline PLC creates, discovers, develops, manufactures and markets pharmaceutical products including respiratory and antiviral, vaccines, over-the-counter (OTC) medicines and health-related ...